Abstract: The invention relates to a method for controlling the start-up phase of a motor vehicle driven by an internal combustion engine (12). The internal combustion engine (12) is started by an electrical machine (16) that can be operated as a motor, and there is a preferably automatically actuatable clutch (50) in the drive train (11) between the internal combustion engine (12) and the electrical machine (16). A faster start-up response can be achieved if the internal combustion engine (12) is driven by the electrical machine (16) when the clutch (50) is engaged during start-up, and if the clutch capacitance (MK) is reduced according to a defined parameter, preferably the engine speed, the time or the torque (ME) of the electrical machine (16) or similar.

Abstract: A compound of formula I wherein R, Ra and Rb are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Abstract: The present invention pertains to the use of a PKC inhibitor in the manufacture of a medicament in the treatment or prevention of diabetic complications.

Abstract: Provided are compounds of Formula (I), which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infraction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of (I) are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g.

Abstract: Disclosed is a method for producing cyclic phosphonic acid anhydrides of formula (III) by a) reacting phosphonic acid derivatives of formula (I) with acetic anhydride at a temperature ranging between 30 and 150° C. while separating a mixture of ethanoic acid and acetic anhydride by means of distillation, b) then reactively distilling the oligomeric phosphonic acid anhydrides of formula (II) obtained in step a) and transforming the same into the corresponding cyclic trimeric phosphonic acid anhydrides of formula (III), wherein n represents a number between 0 and 300 while R represents allyl, aryl, or open-chain, cyclic, or branched C1 to C8 alkyl radicals, aryloxy, allyloxy, or alkoxy comprising open-chain, cyclic, or branched C1 to C8 alkyl radicals. Preferably the cyclic trimeric phosphonic acid anhydrides formed in step b) are immediately dissolved in an organic solvent that exhibits an inert behavior relative thereto.

Abstract: A compound of formula (I) wherein R, R1, and R2, ring A and ring B are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Abstract: A device for plane-parallel attachment of a first module to a sidewall of a second module includes at least one coupling element with clamping projections having beveled end sections. The coupling element includes a guide element with two opposing guide tabs, a locking element, and a stop element, wherein the guide tabs, the locking element, and the stop element abut sidewalls of the connecting element so that the two guide tabs extend from a first opposing pair of the sidewalls, and the locking element and the stop element extend from another opposing pair of the sidewalls perpendicular to the first pair. The first module includes an interlock for captivating the coupling element or elements in the sidewall of the first module, whereas the second module has a receiving part capable of receiving the coupling element or elements captivated in the sidewall of the first module.

Abstract: This invention relates to PKC inhibitors which are able to selectively inhibit e.g. the and optionally 0, isoforms of PKC, and their use in particular in transplantation.

Abstract: A compound of formula I wherein R, Ra, Rb, Rc, Rd and Re are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Abstract: A separator for separating liquid components, in particular oil components, from a gas flow is disclosed including a cyclone and a tank. The liquid separator has a cyclone 1 with a separating chamber 2 including gas supply 3 and gas discharge 4 and a tank 5 which is connected to the cyclone 1 via a connection opening 6. The interior of the tank 5 is filled at least partially with a porous open-pore material 7 in order to interrupt the flow, dampen the flow, dampen the oscillations and/or discharge the liquid.

Abstract: Method of performing condensation reactions, acylations or of preparing heterocycles comprising forming cyclic phosphonic anhydride of the formula (III) by a) reacting phosphonic acid derivatives of formula (I) with acetic anhydride at a temperature ranging between 30 and 150° C. while separating a mixture of ethanoic acid and acetic anhydride by means of distillation, b) then reactively distilling the oligomeric phosphonic acid anhydrides of formula (II) obtained in step a) and transforming the same into the corresponding cyclic trimeric phosphonic acid anhydrides of formula (III), wherein n represents a number between 0 and 300 while R represents allyl, aryl, or open-chain, cyclic, or branched C1 to C8 alkyl radicals, aryloxy, allyloxy, or alkoxy comprising open-chain, cyclic, or branched C1 to C8 alkyl radicals. Preferably the cyclic trimeric phosphonic acid anhydrides formed in step b) are immediately dissolved in an organic solvent that exhibits an inert behavior relative thereto.

Abstract: Provided are compounds of Formula (I), which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infraction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of (I) are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g.

Abstract: Provided are compounds of formula I which have interesting pharmacological properties.

Abstract: Provided are compounds of formula (I) which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula I are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory disease or disorders or autoimmune diseases e.g.

Abstract: The present invention relates to a fluid separation device (10) for separating fluid, oil and oil spray from a gas. This fluid separation device (10) comprises a base carrier (21) in which fluid separator elements (20) in the form of flow-through tubes with worm-like segments (23) arranged therein, are integrated. The worm-like segments (23) at the same time form spiral flow paths (25) for the gas. They have a maximal length of half a pitch of the worm-like segment (23) so that the base carrier (21) together with the associated fluid separator elements (20) may be formed as one piece. Several base carriers may be arranged one after the other in a manner such that individual fluid separator elements of various base carriers form a common flow path for the gas.

Abstract: The present invention relates to a cylinder head cover for covering a cylinder head of a combustion engine. Such cylinder head covers often comprise an oil separator for separating oil and/or oil spray from the blow-by gas of combustion engines. With the present invention the oil separator is formed as a flow-through tube (10) through which the gas with the oil and/or oil spray to be separated flows. The flow-through tube (10) with its longitudinal axis (14) in the flow-through direction lies essentially in the plane of extension of the cylinder head cover (1). A worm-like segment is arranged in the flow-through tube (10), and its thread surfaces (21) form a spiral flow path (2). At the same time the cross section of the flow path lies between 1 mm2 and 800 mm2.

Abstract: This invention relates to the use of a compound of formula I, II, III, or IV, as described in the specification, in transplantation and autoimmune diseases.

Abstract: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.

Abstract: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.